The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...

Miv-cel, a CD19-targeting CAR-T therapy, showed 81% symptom improvement in SPS patients after four months, with significant mobility gains. Kyverna Therapeutics plans to submit a Biologics License ...

Background: Advancements in cancer-targeted immunotherapies have transformed care, yet these therapies present a high likelihood of cytokine release syndrome (CRS), a potentially severe immune-related ...

Yescarta showed a 96% objective response rate and 91% complete response rate in relapsed/refractory follicular lymphoma patients. Two-year outcomes included a 70% duration of response, 64% progression ...

Introduction: The development of robust predictive models for high-grade cytokine release syndrome (CRS) in CAR-T recipients remains limited by sparse clinical trial data. Methods: We analyzed of 496 ...

Epkinly, combined with Revlimid and Rituxan, shows improved progression-free survival and response rates in relapsed or refractory follicular lymphoma. The EPCORE FL-1 trial demonstrated a 79% ...